Sincalide
Kinevac (sincalide) is a protein pharmaceutical. Sincalide was first approved as Kinevac on 1982-01-01. It is known to target gastrin/cholecystokinin type B receptor and cholecystokinin receptor type A.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Kinevac
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
---|---|
J2805 | Injection, sincalide, 5 micrograms |
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colonoscopy | D003113 | — | — | 1 | 4 | — | 5 | ||
Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 1 | — | — | 1 | 1 | 3 |
Colic | D003085 | HP_0011848 | R10.83 | — | 1 | — | 1 | 1 | 3 |
Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | 1 | 1 | — | 2 |
Colonic neoplasms | D003110 | C18 | — | — | — | 1 | 1 | 2 | |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | — | 1 | |
Chronic renal insufficiency | D051436 | N18 | — | — | — | 1 | — | 1 | |
Colonic polyps | D003111 | K63.5 | — | — | — | 1 | — | 1 | |
Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | 1 | — | 1 |
Ileus | D045823 | K56.7 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 1 | — | 3 | 4 | ||
Female infertility | D007247 | EFO_0008560 | N97 | — | — | 1 | — | — | 1 |
Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Stomach diseases | D013272 | — | 1 | — | — | 1 | 2 | ||
Otitis media | D010033 | EFO_0004992 | H66.9 | — | 1 | — | — | — | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | SINCALIDE |
INN | sincalide |
Description | Sincalide is an oligopeptide. |
Classification | Peptide |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CSCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@@H](N)CC(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O |
Identifiers
PDB | — |
CAS-ID | 25126-32-3 |
RxCUI | 9800 |
ChEMBL ID | CHEMBL1121 |
ChEBI ID | — |
PubChem CID | 9833444 |
DrugBank | DB09142 |
UNII ID | M03GIQ7Z6P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CCKBR
CCKBR
CCKAR
CCKAR
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 531 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,537 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more